Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Advanced CancerPain
Interventions
DRUG

Lenalidomide

10 mg by mouth daily

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER